Anika Therapeutics, Inc. (ANIK) Gross margin 2016–2025
Anika Therapeutics, Inc. (ANIK) gross margin by fiscal year — reported gross profit divided by reported revenue.
56.6%FY2025 · since FY2016: 76.8% → 56.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 56.6% | -6.8 pp |
| FY2024 | 63.4% | -4.9 pp |
| FY2023 | 68.3% | +4.0 pp |
| FY2022 | 64.3% | +8.2 pp |
| FY2021 | 56.1% | +3.2 pp |
| FY2020 | 52.9% | -22.0 pp |
| FY2019 | 74.9% | +4.6 pp |
| FY2018 | 70.4% | -5.5 pp |
| FY2017 | 75.9% | -0.9 pp |
| FY2016 | 76.8% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice